Dow Chemical and Cambrex Celebrate the Completion of the Facility for AFFINISOL™ Drug-Solubility

Horgen, Switzerland and Karlskoga, Sweden –  The Dow Chemical Company(NYSE: DOW) and Cambrex (NYSE: CBM) celebrated the completion of the new operational facility for Dow’s Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS) for Drug Solubility Enhancement with a ribbon cutting ceremony at the Cambrex Karlskoga site.

Download news release as PDF

The Cambrex Karlskoga facility expansion began in early 2013. “We are proud to have completed this carefully executed expansion in such a short amount of time,” said Bjarne Sandberg, Managing Director of Cambrex Karlskoga. “This has been a great collaboration with both the Dow and Cambrex teams focused on meeting project goals. This partnership between Dow and Cambrex further demonstrates Cambrex’s commitment to finding solutions that allow our clients to meet a market need in a timely manner.”

The facility completion and start of the HPMCAS product validation marks a year-long journey that began with a solubilization partnership between Dow and Bend Research, announced in October 2012. Starting early 2014, Dow will be able to commercially supply solubility enabling excipients. “We are very pleased with our manufacturing collaboration with Cambrex, which has allowed us to maximize Dow’s polymer science and application expertise, and enter the market with AFFINISOL™ in a short amount of time to help our customers meet their solubility challenges,” said Sarah Eckersley, R&D Director for Dow Pharma & Food Solutions.

“We are enthusiastic about commercially bringing the first solution of our AFFINISOL™ portfolio to the market,” said Marc van Gerwen, Business Director for Dow Pharma & Food Solutions. “Working with Cambrex, we were able promptly address the pharmaceutical industry’s most pressing need: advancing poorly soluble Active Pharmaceutical Ingredients to become therapeutically beneficial oral drug products.”

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visitwww.cambrex.com.

About Dow

Dow (NYSE: DOW) combines the power of science and technology to passionately innovate what is essential to human progress. The Company connects chemistry and innovation with the principles of sustainability to help address many of the world’s most challenging problems such as the need for clean water, renewable energy generation and conservation, and increasing agricultural productivity. Dow’s diversified industry-leading portfolio of specialty chemical, advanced materials, agrosciences and plastics businesses delivers a broad range of technology-based products and solutions to customers in approximately 160 countries and in high growth sectors such as electronics, water, energy, coatings and agriculture. In 2012, Dow had annual sales of $57 billion and employed approximately 54,000 people worldwide. The Company’s more than 5,000 products are manufactured at 188 sites in 36 countries across the globe. References to “Dow” or the “Company” mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted. More information about Dow can be found at www.dow.com.

Contact:  Stephanie Harrison
Marketing Manager
Phone:   +1 201.804.3061
Email:     stephanie.harrison@cambrex.com

Contact:  Nathalie Knabe
The Dow Chemical Company
Phone:   + 49 151 12595663
Email:     nknabe@dow.com

Cambrex Icon
Posted by Cambrex
Tags